Slide 1: Orion Interim Report January–September 2024
Orion Interim Report January–September 2024 29 October 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q3 2024 – Strong underlying growth boosted by milestone payments
Q3 2024 – Strong underlying growth boosted by milestone payments • Two significant milestone payments, in total EUR 7–9/ 7–9/ 130 million, boosted both net sales and EBIT 2024 2023 Change • Underlying business showed strong growth with Nubeqa®, Easyhaler®, Generics and Consumer Health, and Animal He
Slide 4: January–September 2024 results
January–September 2024 results • Two significant milestone payments, in total EUR 1–9/ 1–9/ 130 million, boosted both net sales and operating Change 2024 2023 profit • Underlying business showed strong growth with Net sales, EUR million 1,108.0 868.5 +27.6% Nubeqa®, Easyhaler® and Animal Health busi
Slide 5: Net sales bridge from 1–9/2023 to 1–9/2024
Net sales bridge from 1–9/2023 to 1–9/2024 . . . . . . . . MEUR . . – – 1 Simdax® and dexmedetomidine for human use 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Milestones 4 Easyhaler® produc
Slide 6: Operating profit bridge from 1–9/2023 to 1–9/2024
Operating profit bridge from 1–9/2023 to 1–9/2024 . . . . . . MEUR . . . – – 1 Product & service sales without sales margin and product mix change and exchange rate effect 5 Milestones 2 Product sales margin and product mix change but without exchange rate effect 6 Other operating income and expense
Slide 7: Innovative Medicines EUR 367.8 (167.0) million (+>100%)
Innovative Medicines EUR 367.8 (167.0) million (+>100%) • Net sales include EUR 70 million Nubeqa® Nubeqa® sales booked by Orion1 milestone and EUR 60 million item (milestone) 100 related to conversion of MSD collaboration into a 90 lisence agreement 80 • One Nubeqa® sales milestone of EUR 180 milli
Slide 8: Branded Products EUR 207.9 (188.5) million (+10.3%)
Branded Products EUR 207.9 (188.5) million (+10.3%) 140 • Easyhaler® product portfolio Sales split 120.3 (+18.3)% continued strong 120 4% growth 101.6 100 • Sales volume of the entacapone 8% products increased but due to 80 declining prices the net sales was MEUR 67.7 61.6 60 lower than in the compa
Slide 9: Generics and Consumer Health EUR 386.2 (383.6) million (+0.7%)
Generics and Consumer Health EUR 386.2 (383.6) million (+0.7%) 350 • The revenue of the Generics and Sales split by geographic Consumer Health business 300 286.4 289.7 areas division increased for the first time 250 13% • Reference-priced prescription 200 drugs in Finland showing strong MEUR 10% gro
Slide 10: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth (+20.9%) Animal Health Fermion came from various sources with 100 93.2 70 animal sedatives being the single 90 77.1 60 largest contributor 80 25.8 54.1 53.0 70 50 18.2 60 40 MEUR 50 30 40 30 67.4 58.8 20 20 10 10 0 0 1–9/2023 1–9/2024 1–9/2023 1–9/202
Slide 11: TOP 10 products and total sales split by division
TOP 10 products and total sales split by division EUR vs. Product or product portfolio million 1–9/2023 Sales split in 1–9/2024 1. Nubeqa® 216.3 +79.8% 2. Easyhaler® product portfolio 120.3 +18.3% 3. Entacapone products1 61.6 -8.9% 5% 8% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 25.8 +41.5% 3
Slide 12: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Ongoing ARASTEP / darolutamide 1 Prostate cancer (BCR) Ongoing OMAHA1 / opevesostat 2 Prostate cancer (mCRPC) Ongoing OMAHA2a / opevesostat 2 Prostat
Slide 13: Orion’s climate targets are backed by science
Orion’s climate targets are backed by science Validation from the Science Based Targets initiative (SBTi) confirms that our near-term emissions reduction targets are in line with the latest climate science 70% 78% Orion commits to reduce absolute scope Orion commits that 78% of its suppliers by emis
Slide 14: Outlook for 2024 (updated on 11 September 2024)
Outlook for 2024 (updated on 11 September 2024) Net sales EUR 1,470–1,510 million Operating EUR 370–400 million profit 14 29 October 2024 © Orion Corporation
Slide 15: Upcoming events
Upcoming events Financial Statement Release for 2024 25/2/2025 AGM 2025 planned to be held 3/4/2025 Interim Report 1–3/2025 23/4/2025 Half-Year Financial Report 1–6/2025 18/7/2025 Interim Report 1–9/2025 28/10/2025 16 29 October 2024 © Orion Corporation